California-based AI drug discovery startup Genesis announced it scored a whopping $200 million in an oversubscribed Series B funding round, bringing its total raise to $280 million.
The company also announced that approximately $24 million of SAFE notes from a prior funding round were converted amid the closing of the Series B round.
Andreessen Horowitz and a "U.S.-based life sciences-focused...
